DrugPatentWatch Database Preview
EPZICOM Drug Profile
Which patents cover Epzicom, and when can generic versions of Epzicom launch?
Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA.
The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
Summary for EPZICOM
Recent Clinical Trials for EPZICOM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme Corp. | Phase 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| AIDS Clinical Trials Group | Phase 3 |
Recent Litigation for EPZICOM
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| ViiV Healthcare UK Ltd. v. Lupin Ltd. | 2011-06-29 |
| Glaxo Group Ltd. v. Lupin Ltd. | 2008-08-29 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Teva Pharmaceuticals USA, Inc. | 2015-01-08 |
| Apotex Corp. | 2014-06-02 |
Pharmacology for EPZICOM
Synonyms for EPZICOM
| ((1R,4S)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-enyl)methanol |
| (1R-cis)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| (1R,4S)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| (1R,4S)-Abacavir |
| (1R)-4beta-[2-Amino-6-(cyclopropylamino)-9H-purine-9-yl]-2-cyclopentene-1beta-methanol |
| [(1R,4S)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol |
| 136470-79-6 |
| 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1R-cis)- |
| 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1R,4S)- |
| 2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1R-cis)- |
| Abacavir sulfate impurity A [WHO-IP] |
| AC1LAJJF |
| AKOS015894952 |
| CTK0G9914 |
| DTXSID20332855 |
| ent-Abacavir |
| FT-0660944 |
| I14-32396 |
| NCGC00241110-01 |
| SCHEMBL52190 |
| UNII-X9A7099R51 |
| X9A7099R51 |
| ZINC4400 |
US Patents and Regulatory Information for EPZICOM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EPZICOM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EPZICOM
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | Start Trial |
